UBS Maintains Neutral on TransMedics Group, Raises Price Target to $88
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and raises the price target from $77 to $88.
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and raises the price target from $77 to $88.